IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published 1 day ago
Medical Professional
AML durability of treatment
Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)
Eytan Stein, MD
Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)
Ghaith Abu-Zeinah, MD
Dr. Sandip Patel describes re-challenging with chemotherapy in patients who received 1L osimertinib + chemotherapy. (Video 3/3)
Sandip Patel, MD
Dr. Joshua Richter highlights the patient types that may benefit most from mezigdomide (Video 3/3)
Joshua Richter, MD
Dr. Joe Mendez reviews the watch and wait vorasidenib patient profile in low-grade gliomas (Video 3/3)
Joe Mendez, MD
Dr. Ghaith Abu-Zeinah reviews the risks and threats in essential thrombocythemia (Video 2/3)
Ghaith Abu-Zeinah, MD